Clene (CLNN) 10% holder’s LLC sells blocks of common stock

Rhea-AI Filing Summary

Clene Inc.’s 10% owner Chidozie Ugwumba, through affiliated entity Symbiosis II, LLC, reported a series of indirect open‑market sales of Clene common stock. The LLC sold 15,284 shares at $4.32 on January 29, 5,686 shares at $4.13 on January 30, and 3,800 shares at $4.04 on February 2, 2026. Following the latest transaction, 555,559 shares of Clene common stock are reported as indirectly owned by Symbiosis II, LLC.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ugwumba Chidozie

(Last) (First) (Middle)

609 SW 8TH STREET

SUITE 510

(Street)

BENTONVILLE AR 72712

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/29/2026		S		15,284	D	$4.32	565,045	I	By Symbiosis II, LLC
Common Stock	01/30/2026		S		5,686	D	$4.13	559,359	I	By Symbiosis II, LLC
Common Stock	02/02/2026		S		3,800	D	$4.04	555,559	I	By SymBiosis II, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Chidozie Ugwumba	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Clene Inc. (CLNN) report in this Form 4?

Clene Inc. reported that Symbiosis II, LLC, an entity associated with 10% owner Chidozie Ugwumba, sold blocks of common stock on three dates in early 2026. These were open‑market sales at prices just above $4 per share, reducing but not eliminating the indirect stake.

How many Clene (CLNN) shares were sold and on which dates?

Symbiosis II, LLC sold 15,284 Clene common shares on January 29, 5,686 shares on January 30, and 3,800 shares on February 2, 2026. Each transaction was reported with code “S,” indicating sales of non‑derivative securities in the open market at stated per‑share prices.

At what prices were the Clene Inc. (CLNN) shares sold by Symbiosis II, LLC?

The reported sales occurred at per‑share prices of $4.32 on January 29, $4.13 on January 30, and $4.04 on February 2, 2026. Each price reflects the average sale price for that transaction as disclosed, showing closely grouped trading levels around the $4 range.

How many Clene (CLNN) shares does Symbiosis II, LLC hold after these transactions?

After the February 2, 2026 transaction, the filing shows Symbiosis II, LLC indirectly holding 555,559 shares of Clene common stock. This figure represents the remaining beneficial ownership reported for the entity associated with 10% owner Chidozie Ugwumba following the disclosed open‑market sales.

Is the Clene Inc. (CLNN) Form 4 transaction direct or through an entity?

The transactions are reported as indirect, with ownership described as “By Symbiosis II, LLC.” This indicates the sales and resulting holdings are attributed to the LLC, an entity associated with 10% owner Chidozie Ugwumba, rather than as directly held shares in his personal name.

What does the 10% owner designation mean for Clene (CLNN) in this filing?

The Form 4 identifies Chidozie Ugwumba as a 10% owner of Clene Inc. This status triggers ongoing reporting obligations for changes in beneficial ownership, such as the indirect sales by Symbiosis II, LLC, helping investors track significant shareholder movements in the company’s stock.